ST2对儿童与成人移植后GVHD死亡风险的评估
该前瞻性队列研究纳入6中心415例异基因造血干细胞移植患者,其中≤10岁儿童170例、>10岁245例,于移植前及移植后+7、+14、+21天检测4种血浆生物标志物。移植后ST2、TNFR1、REG3α与≤10岁儿童及>10岁患者的非复发死亡(NRM)相关;校正协变量后,仅≤10岁儿童移植前ST2仍与NRM相关(HR 4.82)。
要点
- 移植后前3周ST2、TNFR1、REG3α对儿童和成人NRM均有预后价值
- ≤10岁儿童移植后ST2>26 ng/mL与NRM强相关(HR 9.13)
- 校正协变量后仅≤10岁儿童移植前ST2仍与NRM相关(HR 4.82)
核心结论
- 移植后前3周检测ST2、TNFR1和REG3α对儿童和成人NRM具有预后价值。
- 移植前ST2是≤10岁儿童NRM的预后标志物,可助额外分层。
- 校正显著协变量后,ST2仅于≤10岁受者中仍与NRM相关(HR 4.82;95%CI 1.89-14.66;P=.0056)。
研究设计与样本
- 前瞻性队列研究,6个中心共纳入415例异基因造血干细胞移植患者。
- ≤10岁儿童170例,>10岁患者245例,2013至2018年入组。
- 移植前及移植后+7、+14、+21天检测ST2、TNFR1、REG3α和IL-6,以各标志物中位数二分高低风险组行landmark分析。
- 试验注册号NCT02194439。
主要发现
- 移植后ST2>26 ng/mL与≤10岁儿童NRM相关(HR 9.13;95%CI 2.74-30.38;P=.0003)。
- 移植后TNFR1>3441 pg/mL与≤10岁儿童NRM相关(HR 4.29;95%CI 1.48-12.48;P=.0073)。
- 移植后REG3α>25 ng/mL与≤10岁儿童NRM相关(HR 7.28;95%CI 2.05-25.93;P=.0022)。
- >10岁患者中移植后ST2(HR 2.60;95%CI 1.15-5.86;P=.021)和REG3α(HR 2.57;95%CI 1.19-5.55;P=.016)与NRM相关,TNFR1无统计学意义(HR 2.09;95%CI 0.96-4.58;P=.06)。
- 纳入移植前标志物时,仅ST2在两个年龄组中均保持显著。
关键数值与推荐
- 移植后ST2高风险的切点为>26 ng/mL。
- 移植后TNFR1高风险的切点为>3441 pg/mL。
- 移植后REG3α高风险的切点为>25 ng/mL。
- 校正协变量(种族/民族、恶性疾病、移植物、GVHD预防)后,≤10岁儿童ST2与NRM相关(HR 4.82;95%CI 1.89-14.66;P=.0056)。
临床怎么用
- 移植后前3周可检测ST2、TNFR1和REG3α以评估儿童和成人NRM风险。
- 对≤10岁儿童,移植前检测ST2有助于识别高风险者并额外分层。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Assessment of prognostic biomarkers of nonrelapse mortality (NRM) after allogeneic hematopoietic cell transplantation (HCT) in the pediatric age group is lacking. To address this need, we conducted a prospective cohort study with 415 patients at 6 centers: 170 were children age 10 years or younger and 245 were patients older than age 10 years (both children and adults were accrued from 2013 to 2018). The following 4 plasma biomarkers were assessed pre-HCT and at days +7, +14, and +21 post-HCT: stimulation-2 (ST2), tumor necrosis factor receptor 1 (TNFR1), regenerating islet-derived protein 3α (REG3α), and interleukin-6 (IL-6). We performed landmark analyses for NRM, dichotomizing the cohort at age 10 years or younger and using each biomarker median as a cutoff for high- and low-risk groups. Post-HCT biomarker analysis showed that ST2 (>26 ng/mL), TNFR1 (>3441 pg/mL), and REG3α (>25 ng/mL) are associated with NRM in children age 10 years or younger (ST2: hazard ratio [HR], 9.13; 95% confidence interval [CI], 2.74-30.38; P = .0003; TNFR1: HR, 4.29; 95% CI, 1.48-12.48; P = .0073; REG3α: HR, 7.28; 95% CI, 2.05-25.93; P = .0022); and in children and adults older than age 10 years (ST2: HR, 2.60; 95% CI, 1.15-5.86; P = .021; TNFR1: HR, 2.09; 95% CI, 0.96-4.58; P = .06; and REG3α: HR, 2.57; 95% CI, 1.19-5.55; P = .016). When pre-HCT biomarkers were included, only ST2 remained significant in both cohorts. After adjustment for significant covariates (race/ethnicity, malignant disease, graft, and graft-versus-host-disease prophylaxis), ST2 remained associated with NRM only in recipients age 10 years or younger (HR, 4.82; 95% CI, 1.89-14.66; P = .0056). Assays of ST2, TNFR1, and REG3α in the first 3 weeks after HCT have prognostic value for NRM in both children and adults. The presence of ST2 before HCT is a prognostic biomarker for NRM in children age 10 years or younger allowing for additional stratification. This trial was registered at www.clinicaltrials.gov as #NCT02194439.
引用
- Rowan CM, Pike F, Cooke KR, et al. Assessment of ST2 for risk of death following graft-versus-host disease in pediatric and adult age groups. Blood. 2020. PMID: 31972009. doi:10.1182/blood.2019002334
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。